- Home
- NMCO vs CRMD Comparison
NMCO vs CRMD Comparison
Compare NMCO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- CRMD
- Stock Information
- Founded
- NMCO 2019
- CRMD 2006
- Country
- NMCO United States
- CRMD United States
- Employees
- NMCO N/A
- CRMD N/A
- Industry
- NMCO Finance/Investors Services
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- NMCO Finance
- CRMD Health Care
- Exchange
- NMCO Nasdaq
- CRMD Nasdaq
- Market Cap
- NMCO 611.9M
- CRMD 576.4M
- IPO Year
- NMCO N/A
- CRMD 2010
- Fundamental
- Price
- NMCO $10.75
- CRMD $11.90
- Analyst Decision
- NMCO
- CRMD Strong Buy
- Analyst Count
- NMCO 0
- CRMD 6
- Target Price
- NMCO N/A
- CRMD $15.67
- AVG Volume (30 Days)
- NMCO 207.6K
- CRMD 1.2M
- Earning Date
- NMCO 01-01-0001
- CRMD 10-30-2024
- Dividend Yield
- NMCO 5.43%
- CRMD N/A
- EPS Growth
- NMCO N/A
- CRMD N/A
- EPS
- NMCO N/A
- CRMD N/A
- Revenue
- NMCO N/A
- CRMD $12,262,234.00
- Revenue This Year
- NMCO N/A
- CRMD N/A
- Revenue Next Year
- NMCO N/A
- CRMD $300.00
- P/E Ratio
- NMCO N/A
- CRMD N/A
- Revenue Growth
- NMCO N/A
- CRMD 41184.20
- 52 Week Low
- NMCO $8.52
- CRMD $2.89
- 52 Week High
- NMCO $11.64
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- NMCO 48.47
- CRMD 73.05
- Support Level
- NMCO $10.60
- CRMD $7.91
- Resistance Level
- NMCO $10.82
- CRMD $11.50
- Average True Range (ATR)
- NMCO 0.12
- CRMD 0.56
- MACD
- NMCO 0.03
- CRMD 0.44
- Stochastic Oscillator
- NMCO 82.93
- CRMD 98.66
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.